Biopoin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical success of epoetin therapies, rising dialysis population, increased chemotherapy related anemia, hospital based anemia protocols, improved hemoglobin monitoring.

The growth in the forecast period can be attributed to growth in chronic renal failure cases, expansion of oncology supportive care, increased access to biosimilar epoetins, aging population trends, focus on anemia related fatigue management. Major trends in the forecast period include rising use of erythropoiesis stimulating agents, growing anemia burden in chronic kidney disease, expansion of supportive oncology care, shift toward long acting anemia management therapies, improved quality of life focus in chronic anemia patients.

The rising incidence of chronic kidney disease is expected to drive the growth of the biopoin market going forward. Chronic kidney disease (CKD) is a long-term condition marked by the gradual decline of kidney function, which impairs the kidneys’ ability to filter waste and excess fluids from the blood. The increasing incidence of CKD is primarily driven by rising rates of diabetes, hypertension, and unhealthy diets. In CKD, reduced erythropoietin production often leads to anemia, causing fatigue and weakness. Biopoin, containing epoetin theta, stimulates red blood cell production, increases hemoglobin levels, and improves quality of life. For example, in October 2024, the National Health Service (UK) reported that nearly half of adults aged 75 and older are affected by stages 1 to 5 CKD (48%), including over a third who experience the more severe stages 3 to 5 (36%). Additionally, Oxford Academic reported in June 2023 that the number of people with CKD in the UK is projected to rise by 4% between 2022 and 2032, growing from 8.27 million to 8.61 million. Consequently, the rising incidence of CKD is contributing to the growth of the biopoin market.

The growing demand for personalized medicine is also expected to support the expansion of the biopoin market. Personalized medicine tailors healthcare based on an individual’s unique genetic, environmental, and lifestyle factors. Advances in genetic research enable precise identification of disease-related genetic markers, allowing healthcare providers to deliver more effective, customized treatments. Biopoin therapies target specific molecular markers or mutations in a patient’s disease, offering more precise and effective treatments. This approach enhances efficacy, reduces side effects, and shifts away from a one-size-fits-all model toward individualized care. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the biopoin market.

The increasing prevalence of anemia is expected to further propel the growth of the biopoin market. Anemia is a condition characterized by a deficiency in red blood cells or hemoglobin, which reduces the blood’s capacity to transport oxygen to body tissues. The rising prevalence of anemia is largely due to nutritional deficiencies, as insufficient intake of iron, vitamin B12, and folate impairs red blood cell production. Biopoin supports anemia management by providing accurate diagnostics and monitoring, enabling timely interventions, and improving treatment efficacy and overall patient outcomes. For example, in April 2024, the World Health Organization reported that approximately 30.7% of women aged 15-49 years suffered from anemia in 2023. Consequently, the increasing prevalence of anemia is driving the growth of the biopoin market.

Major companies operating in the biopoin market are Teva Pharmaceutical Industries.

North America was the largest region in the biopoin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopoin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopoin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately impacted the biopoin market by increasing costs related to recombinant epoetin production, pharmaceutical excipients, and distribution logistics. These impacts are most visible in hospital pharmacies and specialty clinics. Higher tariffs have placed pricing pressure on long term anemia treatments. At the same time, tariffs are supporting regional biologics manufacturing expansion. This is strengthening supply continuity for erythropoiesis stimulating agents.

The biopoin market research report is one of a series of new reports that provides biopoin market statistics, including biopoin industry global market size, regional shares, competitors with a biopoin market share, detailed biopoin market segments, market trends and opportunities, and any further data you may need to thrive in the biopoin industry. This biopoin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biopoin is a biopharmaceutical therapy used to treat anemia, particularly in adults with chronic renal failure or undergoing chemotherapy for non-myeloid cancers. It contains epoetin theta, a recombinant form of erythropoietin, which stimulates red blood cell production. Biopoin also helps reduce anemia-related fatigue and weakness by increasing hemoglobin levels.

The primary indications of biopoin include anemia associated with chronic kidney disease, cancer-related anemia, surgical anemia, and other conditions. Anemia in chronic kidney disease (CKD) occurs when damaged kidneys produce less erythropoietin, a hormone essential for red blood cell production. This results in lower hemoglobin levels, causing fatigue and reduced oxygen-carrying capacity. Treatments often involve erythropoiesis-stimulating agents, iron supplementation, and occasionally blood transfusions. Biopoin therapy plays a key role in improving quality of life for CKD patients. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adults, elderly patients, and pediatric populations.

The biopoin market consists of sales of pre-filled syringes and erythropoiesis-stimulating agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.